Trial Profile
A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients With Advanced Solid Tumors, With Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary) ; Everolimus (Primary) ; Exemestane
- Indications Advanced breast cancer; Cervical cancer; Gastric cancer; Intestinal cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Parathyroid cancer; Renal cell carcinoma; Solid tumours; Uterine cancer
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 05 May 2021 Results published in the European Journal of Cancer
- 11 Jul 2019 Status changed from active, no longer recruiting to completed.
- 09 Jan 2019 Planned End Date changed from 30 Nov 2018 to 28 Jan 2019.